# Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

> **NCT07284433** · PHASE1,PHASE2 · RECRUITING · sponsor: **AvenCell Therapeutics, Inc.** · enrollment: 178 (estimated)

## Conditions studied

- Lymphoma Diffuse Large B-cell
- Leukemia and Lymphoma
- Leukemia Relapse
- Lymphoma Receiving CAR-T Therapy

## Interventions

- **OTHER:** Cyclophosphamide (Non-IMP, Lymphodepletion)
- **OTHER:** Fludarabine (Non-IMP, Lymphodepletion)
- **DRUG:** Allo-QuadCAR01-T

## Key facts

- **NCT ID:** NCT07284433
- **Lead sponsor:** AvenCell Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2029-04-27
- **Final completion:** 2029-11-02
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284433, "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07284433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*